Launched by Pharmacyclics vets, preclinical cancer start-up Biomea Fusion seeks short path to IPO

Less than three months after revealing its series A round, preclinical start-up Biomea Fusion has filed for a NASDAQ listing to fund development of its first irreversible small-molecule cancer therapy, a menin inhibitor that the company intends to study for leukemias initially.

Founded in 2017 by two former executives at Pharmacyclics Inc., which AbbVie Inc. (NYSE:ABBV) acquired in 2015 for $21 billion, Biomea Fusion Inc. uses its platform to design irreversible therapeutics that bind permanently to their targets, potentially offering higher selectivity, reduced exposure and deeper, more durable responses than conventional reversible drugs...